Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
【译】阿达木单抗治疗是降低溃疡性结肠炎患者的住院风险。
For adalimumab, etanercept and rituximab, an increase of at least 40% was seen in the number of people experiencing improved symptoms, when the drugs were compared to placebos.
阿达木单抗、依那西普和依那西普与安慰剂相对比,可以看到至少增加40%以上症状改善的病人。
For adalimumab, etanercept and rituximab, an increase of at least 40% was seen in the number of people experiencing improved symptoms, when the drugs were compared to placebos.
阿达木单抗、依那西普和依那西普与安慰剂相对比,可以看到至少增加40%以上症状改善的病人。
应用推荐